Biofilm switch and immune response determinants at early stages of infection

Trends in Microbiology

Volumn 21, Issue 8, 2013, Pages 364-371

  Valle, Jaione ^a   Solano, Cristina ^a   García, Begoña ^a   Toledo Arana, Alejandro ^a   Lasa, Iñigo ^a  

^a PUBLIC UNIVERSITY OF NAVARRE   (Spain)

Author keywords

Biofilm; C di GMP; CGAS; Chronic infection; Innate immune response; PAMPs; STING; Type I interferon

Indexed keywords

ARGINASE 1; CYCLIC AMP; CYCLIC GMP; DINUCLEOTIDE; INTERFERON; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR 2;

ADAPTIVE IMMUNITY; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BIOFILM; CYTOKINE PRODUCTION; HOST CELL; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MACROPHAGE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

BIOFILM; C-DI-GMP; CGAS; CHRONIC INFECTION; INNATE IMMUNE RESPONSE; PAMPS; STING; TYPE I INTERFERON;

ANIMALS; BACTERIA; BACTERIAL PHYSIOLOGICAL PHENOMENA; BIOFILMS; DINUCLEOSIDE PHOSPHATES; HUMANS; IMMUNITY, INNATE; INTERFERON TYPE I; NUCLEOTIDES, CYCLIC; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; VIRULENCE; VIRULENCE FACTORS;

BACTERIA (MICROORGANISMS);

EID: 84881027599     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2013.05.008     Document Type: Review

References (81)

1. Costerton J., et al. Bacterial biofilms in nature and disease. Annu. Rev. Microbiol. 1987, 41:435-464.
2. Costerton J.W., et al. Bacterial biofilms: a common cause of persistent infections. Science 1999, 284:1318-1322.
3. Sutherland I. The biofilm matrix - an immobilized but dynamic microbial environment. Trends Microbiol. 2001, 9:222-227.
4. Mah T.F., O'Toole G.A. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 2001, 9:34-39.
5. Joo H-S., Otto M. Molecular basis of in vivo biofilm formation by bacterial pathogens. Chem. Biol. 2012, 19:1503-1513.
6. Biofilm Infections 2011, Springer. T. Bjarnsholt (Ed.).
7. Sauer K., Camper A.K. Characterization of phenotypic changes in Pseudomonas putida in response to surface-associated growth. J. Bacteriol. 2001, 183:6579-6589.
8. Reid D.W., et al. Iron deficiency in cystic fibrosis: relationship to lung disease severity and chronic Pseudomonas aeruginosa infection. Chest 2002, 121:48-54.
9. Martino P.D., et al. Indole can act as an extracellular signal to regulate biofilm formation of Escherichia coli and other indole-producing bacteria. Can. J. Microbiol. 2003, 49:443-449.
10. Karatan E., et al. NspS, a predicted polyamine sensor, mediates activation of Vibrio cholerae biofilm formation by norspermidine. J. Bacteriol. 2005, 187:7434-7443.
11. Patel C.N., et al. Polyamines are essential for the formation of plague biofilm. J. Bacteriol. 2006, 188:2355-2363.
12. Karatan E., Watnick P. Signals, regulatory networks, and materials that build and break bacterial biofilms. Microbiol. Mol. Biol. Rev. 2009, 73:310-347.
13. Mikkelsen H., et al. Key two-component regulatory systems that control biofilm formation in Pseudomonas aeruginosa. Environ. Microbiol. 2011, 13:1666-1681.
14. Kong W., et al. Hybrid sensor kinase PA1611 in Pseudomonas aeruginosa regulates transitions between acute and chronic infection through direct interaction with RetS. Mol. Microbiol. 2013, 88:784-797.
15. Romling U., et al. Cyclic di-GMP: the first 25 years of a universal bacterial second messenger. Microbiol. Mol. Biol. Rev. 2013, 77:1-52.
16. Simm R., et al. GGDEF and EAL domains inversely regulate cyclic di-GMP levels and transition from sessility to motility. Mol. Microbiol. 2004, 53:1123-1134.
17. Tamayo R., et al. Roles of cyclic diguanylate in the regulation of bacterial pathogenesis. Annu. Rev. Microbiol. 2007, 61:131-148.
18. Solano C., et al. Genetic reductionist approach for dissecting individual roles of GGDEF proteins within the c-di-GMP signaling network in Salmonella. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:7997-8002.
19. Romling U., et al. C-di-GMP: the dawning of a novel bacterial signalling system. Mol. Microbiol. 2005, 57:629-639.
20. Jenal U. Cyclic di-guanosine-monophosphate comes of age: a novel secondary messenger involved in modulating cell surface structures in bacteria?. Curr. Opin. Microbiol. 2004, 7:185-191.
21. Meissner A., et al. Pseudomonas aeruginosa cupA-encoded fimbriae expression is regulated by a GGDEF and EAL domain-dependent modulation of the intracellular level of cyclic diguanylate. Environ. Microbiol. 2007, 9:2475-2485.
22. Starkey M., et al. Pseudomonas aeruginosa rugose small-colony variants have adaptations that likely promote persistence in the cystic fibrosis lung. J. Bacteriol. 2009, 191:3492-3503.
23. Malone J.G., et al. The YfiBNR signal transduction mechanism reveals novel targets for the evolution of persistent Pseudomonas aeruginosa in cystic fibrosis airways. PLoS Pathog. 2012, 8:e1002760.
24. Byrd M.S., et al. Direct evaluation of Pseudomonas aeruginosa biofilm mediators in a chronic infection model. Infect. Immun. 2011, 79:3087-3095.
25. Pultz I.S., et al. The response threshold of Salmonella PilZ domain proteins is determined by their binding affinities for c-di-GMP. Mol. Microbiol. 2012, 86:1424-1440.
26. Bejerano-Sagie M., et al. A checkpoint protein that scans the chromosome for damage at the start of sporulation in Bacillus subtilis. Cell 2006, 125:679-690.
27. Witte G., et al. Structural biochemistry of a bacterial checkpoint protein reveals diadenylate cyclase activity regulated by DNA recombination intermediates. Mol. Cell 2008, 30:167-178.
28. Corrigan R.M., et al. c-di-AMP is a new second messenger in Staphylococcus aureus with a role in controlling cell size and envelope stress. PLoS Pathog. 2011, 7:e1002217.
29. Woodward J.J., et al. c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response. Science 2010, 328:1703-1705.
30. Kamegaya T., et al. Identification of a Streptococcus pyogenes SF370 gene involved in production of c-di-AMP. Nagoya J. Med. Sci. 2011, 73:49-57.
31. Götz F. Staphylococcus and biofilms. Mol. Microbiol. 2002, 43:1367-1378.
32. Otto M. Staphylococcal infections: mechanisms of biofilm maturation and detachment as critical determinants of pathogenicity. Annu. Rev. Med. 2013, 64:175-188.
33. Medzhitov R., Janeway C. The Toll receptor family and microbial recognition. Trends Microbiol. 2000, 8:452-456.
34. Barker J.R., et al. STING-dependent recognition of cyclic di-AMP mediates type I interferon responses during Chlamydia trachomatis infection. mBio 2013, 4:e00018-13.
35. Barbalat R., et al. Nucleic acid recognition by the innate immune system. Annu. Rev. Immunol. 2011, 29:185-214.
36. Blander J.M., Sander L.E. Beyond pattern recognition: five immune checkpoints for scaling the microbial threat. Nat. Rev. Immunol. 2012, 12:215-225.
37. Burdette D.L., Vance R.E. STING and the innate immune response to nucleic acids in the cytosol. Nat. Immunol. 2013, 14:19-26.
38. McWhirter S.M., et al. A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J. Exp. Med. 2009, 206:1899-1911.
39. Abdullah Z., et al. RIG-I detects infection with live Listeria by sensing secreted bacterial nucleic acids. EMBO J. 2012, 31:4153-4164.
40. Shaw N., et al. Binding of bacterial secondary messenger molecule c di-GMP is a STING operation. Protein Cell 2013, 4:117-129.
41. Sauer J-D., et al. The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of STING in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect. Immun. 2011, 79:688-694.
42. Burdette D.L., et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature 2011, 478:515-518.
43. Jin L., et al. MPYS is required for IFN response factor 3 activation and type I IFN production in the response of cultured phagocytes to bacterial second messengers cyclic-di-AMP and cyclic-di-GMP. J. Immunol. 2011, 187:2595-2601.
44. Parvatiyar K., et al. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nat. Immunol. 2012, 13:1155-1161.
45. Bowie A.G. Innate sensing of bacterial cyclic dinucleotides: more than just STING. Nat. Immunol. 2012, 13:1137-1139.
46. Ouyang S., et al. Structural analysis of the STING adaptor protein reveals a hydrophobic dimer interface and mode of cyclic di-GMP Binding. Immunity 2012, 36:1073-1086.
47. Paul R., et al. Cell cycle-dependent dynamic localization of a bacterial response regulator with a novel di-guanylate cyclase output domain. Genes Dev. 2004, 18:715-727.
48. Weinhouse H., et al. c-di-GMP-binding protein, a new factor regulating cellulose synthesis in Acetobacter xylinum. FEBS Lett. 1997, 416:207-211.
49. Sun L., et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013, 339:786-791.
50. Wu J., et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 2013, 339:826-830.
51. Rosen D.A., et al. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med. 2007, 4:e329.
52. Garcia-Medina R., et al. Pseudomonas aeruginosa acquires biofilm-like properties within airway epithelial cells. Infect. Immun. 2005, 73:8298-8305.
53. Clement S., et al. Evidence of an intracellular reservoir in the nasal mucosa of patients with recurrent Staphylococcus aureus rhinosinusitis. J. Infect. Dis. 2005, 192:1023-1028.
54. Hensen S.M., et al. Location of Staphylococcus aureus within the experimentally infected bovine udder and the expression of capsular polysaccharide type 5 in situ. J. Dairy Sci. 2000, 83:1966-1975.
55. Ebensen T., et al. The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties. Vaccine 2007, 25:1464-1469.
56. Karaolis D.K.R., et al. Bacterial c-di-GMP is an immunostimulatory molecule. J. Immunol. 2007, 178:2171-2181.
57. Hu D-L., et al. c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection. Vaccine 2009, 27:4867-4873.
58. Libanova R., et al. Cyclic di-nucleotides: new era for small molecules as adjuvants. Microb. Biotechnol. 2011, 5:168-176.
59. Chen W., et al. The potential of 3',5'-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant. Vaccine 2010, 28:3080-3085.
60. Hengge R. Cyclic-di-GMP reaches out into the bacterial RNA world. Sci. Signal. 2010, 3:pe44.
61. Schwartz K.T., et al. Hyperinduction of host beta interferon by a Listeria monocytogenes strain naturally overexpressing the multidrug efflux pump MdrT. Infect. Immun. 2012, 80:1537-1545.
62. +) phenotype of Yersinia pestis is posttranscriptional. J. Bacteriol. 2004, 186:1638-1647.
63. Decker T., et al. The yin and yang of type I interferon activity in bacterial infection. Nat. Rev. Immunol. 2005, 5:675-687.
64. Ishii K.J., et al. Host innate immune receptors and beyond: making sense of microbial infections. Cell Host Microbe 2008, 3:352-363.
65. Kaplan A., et al. Failure to induce IFN-β production during Staphylococcus aureus infection contributes to pathogenicity. J. Immunol. 2012, 189:4537-4545.
66. Gratz N., et al. Group A streptococcus activates type I interferon production and MyD88-dependent signaling without involvement of TLR2, TLR4, and TLR9, TLR4, and TLR9. J. Biol. Chem. 2008, 283:19879-19887.
67. Xiao N., et al. The Tpl2 mutation Sluggish impairs type I IFN production and increases susceptibility to group B streptococcal disease. J. Immunol. 2009, 183:7975-7983.
68. Mancuso G., et al. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria. J. Immunol. 2007, 178:3126-3133.
69. O'Connell R.M., et al. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J. Exp. Med. 2004, 200:437-445.
70. Auerbuch V., et al. Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J. Exp. Med. 2004, 200:527-533.
71. Carrero J.A., et al. Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection. J. Exp. Med. 2004, 200:535-540.
72. Robinson N., et al. Type I interferon induces necroptosis in macrophages during infection with Salmonella enterica serovar Typhimurium. Nat. Immunol. 2012, 13:954-962.
73. Cramton S., et al. The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is required for biofilm formation. Infect. Immun. 1999, 67:5427-5433.
74. Wang X., et al. The pgaABCD locus of Escherichia coli promotes the synthesis of a polysaccharide adhesin required for biofilm formation. J. Bacteriol. 2004, 186:2724-2734.
75. Maira-Litran T., et al. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine. Infect. Immun. 2005, 73:6752-6762.
76. Vuong C., et al. Polysaccharide intercellular adhesin (PIA) protects Staphylococcus epidermidis against major components of the human innate immune system. Cell. Microbiol. 2004, 6:269-275.
77. Kropec A., et al. Poly-N-acetylglucosamine production in Staphylococcus aureus is essential for virulence in murine models of systemic infection. Infect. Immun. 2005, 73:6868-6876.
78. Cerca N. Comparative antibody-mediated phagocytosis of Staphylococcus epidermidis cells grown in a biofilm or in the planktonic state. Infect. Immun. 2006, 74:4849-4855.
79. Schommer N.N., et al. Staphylococcus epidermidis uses distinct mechanisms of biofilm formation to interfere with phagocytosis and activation of mouse macrophage-like cells 774A.1. Infect. Immun. 2011, 79:2267-2276.
80. Thurlow L.R., et al. Staphylococcus aureus biofilms prevent macrophage phagocytosis and attenuate inflammation in vivo. J. Immunol. 2011, 186:6585-6596.
81. Hanke M.L., et al. Targeting macrophage activation for the prevention and treatment of Staphylococcus aureus biofilm infections. J. Immunol. 2013, 190:2159-2168.